An observational study in Schizophrenia / Schizoaffective Disorder and Depression / Major Depressive Disorder, sponsored by The Royal Ottawa Mental Health Centre. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-03-23.
Sponsored by The Royal Ottawa Mental Health Centre · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 193 studies in Schizophrenia with a site in Canada — 29 open to participants now, 37 under way, 1 of them phase 3. Schizophrenia · Canada.
Among the 193 studies in Schizophrenia with a site in Canada, this one is the 19th largest by planned enrollment of the 30 observational ones that give a count, is one of 12 that started in 2019, is one of 30 observational ones, reaches primary completion later than 15 of the 36 other live ones, and was the 144th registered.
3,567 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.
Browse Schizophrenia studies →29 of the 193 studies in Schizophrenia with a site in Canada are open now. Recruiting first, the newest first:
Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Sites in Canada, United States, Australia and 8 more countries
Ages 5–17
University of Toronto · Sites in Canada
Ages 18+
Douglas Mental Health University Institute · Sites in Canada
Ages 18–65
University of Ottawa · Sites in Canada
Ages 18–85
Ciusss de L'Est de l'Île de Montréal · Sites in Canada
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
193 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 24 · Phase 3 34 · Phase 4 19
First in 1999; this study’s year is marked. 12 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is below the median of 178 across 507 observational studies indexed under Schizophrenia.
Median enrollment 77 across the 161 interventional studies, 109 across the 30 observational. Of the 135 that completed or were terminated, 37 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 193 have an industry lead sponsor. The 10 most frequent:
The Royal Ottawa Mental Health Centre is the lead sponsor of 22 studies on the registry; 16 are open to participants now.
The Royal Ottawa Mental Health Centre has 9 studies filed under Schizophrenia — fewer than ten, so there is no comparison to draw.
12 of the studies in Schizophrenia with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01545999Centre for Addiction and Mental HealthPaired Associative Stimulation in the Dorsolateral Prefrontal Cortex in Patients With Schizophrenia | 2026-12 |
| NCT05748990Centre for Addiction and Mental HealthDoes Abnormal Insulin Action in the Brain Underlie Cognitive and Metabolic Dysfunction in Schizophrenia | 2026-12-31 |
| NCT03788811diaMentis Inc.ERG Components in Schizophrenia and Bipolar Disorder Type I | 2026-12-31 |
| NCT05731414University of TorontoOutcomes From Remediation and Behavioural Intervention Techniques | 2027-01-31 |
| NCT06856161Fraser HealthA Novel Blood Test as a Biomarker in Mental Health | 2027-03-15 |
Add all 12 to your calendar (.ics) → With an account.
Among the 193 studies in Schizophrenia with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Schizophrenia and depression are among the most disabling disorders in all of medicine. Cognitive deficits play a key role in patients' disability, affecting their capacity to contribute actively to society by sustaining employment or academic activity. Moreover, cognitive difficulties tend to persist even after the stabilization of other clinical symptoms. Verbal memory and emotion regulation are two important cognitive domains that are impaired in schizophrenia and depression and are associated with patients' functional outcomes. In this study, brain imaging is used to investigate the brain mechanisms underlying these cognitive deficits in these populations.
This study uses Functional Magnetic Resonance Imaging (fMRI) which is a technique that takes a 3D picture of the brain using magnetic fields. It allows researchers to estimate how active different regions of the brain are. The aim of this study is to use fMRI to better understand the cognitive problems that individuals living with schizophrenia, schizoaffective disorder, or depression experience.
The study will involve three visits at The Royal's Institute of Mental Health Research in Ottawa, Canada. Each visit will last about 2.5 hours long.
Visits 1 and 2: Participants are asked to fill out several questionnaires on a computer. Participants are also asked to answer some questions about their current and past mental health as well as perform some tasks involving general thinking skills.
Visit 3: Participants will complete a brain scan using fMRI. Throughout the experiment, participants will perform three short tasks in the fMRI scanner. Participants will use buttons to answer some questions in response to some words and pictures.
Individuals with an official diagnosis of: Schizophrenia, Schzioaffective or Major Depressive Disorders.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinical group
Clinical group
Control group
Measuring brain activity using resting-state and task-based functional MRI
To better understand the mechanisms underlying cognitive problems in our populations of interest
Time frame: Final Visit (Visit 3)
Plan to share: Yes — De-identified data collected from this study may be shared with other researchers at the Royal's Institute of Mental Health Research for analyses and re-analyses. Variables of the study and scripts used for analyses will be made available to the public. De-identified data will also be shared with the general public upon request. Data that can connect with participants' identity will NOT be used or shared for analyses.
Supporting information: Statistical analysis plan, Analytic code
Time frame: De-identified data will become available upon completion of the study and once results have been published in an academic journal (anticipated time frame: the year of 2024).
No publications or documents are linked to this record.
Started Dec 2019 (actual). Primary completion is estimated for Oct 2026, 81 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Royal Ottawa Mental Health Centre